Abstract:Objective: To investigate the relationship between early-stage renal acute rejection(AR) and the level of Fractalkine in urine, explore the diagnostic and noninvasive monitoring value in early stage after transplantation by measurement of urine Fractalkine. Methods: Urine samples were examined from renal transplant patients between January 2006 and October 2009. A total of 155 patients were enrolled, including 49 with biopsy-proved AR, 58 patients with stable renal function and no abnormal histological findings, 10 patients with subclinical rejection in protocol biopsy, 9 patients with biopsy-proven acute tubular necrosis and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urine samples were also collected from 40 healthy controls. Fractalkine was measured in urine samples using a commercial human Fractalkine enzyme-linked immunosorbent assay (ELISA) kit. Immunohistochemistry for Fractalkine expression was performed on biopsies from renal transplant patients with AR and non-AR. Results: Forty-nine patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with stable renal function and healthy controls[(429.1±56.1)vs (94.6±8.4), (84.5±8.9)ng/mmol creatine, both P<0.001]. Patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with acute tubular necrosis and chronic allograft nephropathy[(429.1±56.1)vs(133.0±9.8), (183.0±18.9)ng/mmol creatine, both P<0.001]. Receiver operating characteristic(ROC)curve was constructed to determine the discriminatory power of Fractalkine levels for diagnosis of AR. The area under ROC curve was 0.920(95% CI: 0.875-0.969, P<0.001), which showed that Fractalkine was a suitable marker for the diagnosis of AR. At a cut-off point of 157.5 ng/mmol creatinine, the sensitivity was 83.7% and the specificity was 84.5% (P<0.001). The dynamic level of urinary Fractalkine in AR patients within 3 weeks after transplantation fluctuated above 300 ng/mmol creatine, which is remarkably higher than patients with stable renal function (below 200 ng/mmol creatinine). Conclusions: As a noninvasive monitoring method, Fractalkine in urine may be a new approach for detection of AR as well as useful to predict response to antirejection therapy. It has good sensitivity and specificity. Besides, measurement of Fractalkine in urine is a simple, inexpensive method for the routine clinical monitoring after kidney transplantation.

Diagnosis of C4d+ Renal Allograft Acute Humoral Rejection by Urine Protein Fingerprint Analysis.

C4d as a significant predictor for humoral rejection in renal allografts.

Non-invasive detection of acute renal allograft rejection by measurement of vascular endothelial growth factor in urine.

Diagnosis of Renal Allograft Subclinical Rejection by Urine Protein Fingerprint Analysis.

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Effect of Acute Cellular Rejection with C4d Deposition on Renal Allograft Survival

Urinary C-X-C Motif Chemokines 13 is a Noninvasive Biomarker of Antibody-Mediated Renal Allograft Rejection

Artificial Urinary Biomarkers for Early Diagnosis of Acute Renal Allograft Rejection

Detection of renal allograft dysfunction with characteristic protein fingerprint by serum proteomic analysis

Peritubular Capillaritis in Early Renal Allograft Dysfunction is an Indicator of Acute Rejection.

Donor-derived cell-free DNA can discriminate acute rejection types after kidney transplantation

Characterization of Acute Renal Allograft Rejection by Human Serum Proteomic Analysis.

Peritubular Capillary C4d Deposition in Acute Renal Allograft Rejection

Prediction of Acute Cellular Renal Allograft Rejection by Urinary Metabolomics Using MALDI-FTMS

Capillary Deposition of Complement C4d and C3d in Chinese Renal Allograft Biopsies.

Acute Renal Allograft Rejection is Associated with Increased Levels of Vascular Endothelial Growth Factor in the Urine

SIMULTANEOUSLY DETECTION OF DDCFDNA IN PLASMA AND URINE ASSIST TO DETERMINE THE TYPE OF REJECTION IN RENAL TRANSPLANT PATIENTS

Clinical Significance of Complement Split Product C4d Deposition in Peritubular Capillaries in Acute Renal Allograft Rejection

[Noninvasive Diagnostic and Predictive Value in Renal Transplant Recipients with Acute Rejection by Measurement of Urine Fractalkine].

Usage of urine flow cytometry in diagnosing the acute renal allograft rejection

Urine protein profiling identified alpha-1-microglobulin and haptoglobin as biomarkers for early diagnosis of acute allograft rejection following kidney transplantation